Scientists from Jordan Ministry of Higher Education Scientific Research and the Hashemite University have identified doxorubicin and thymoquinone hybridized compounds with reduced side effects reported to be useful for the treatment of breast cancer.

Lario Therapeutics Ltd. has synthesized voltage-dependent R-type calcium channel subunit α-1E (Cav2.3) blockers reported to be useful for the treatment of epilepsy, neurodegeneration, neurodevelopmental disorders, Parkinson’s disease, cerebral vasospasm and endocrine disorders.

Hainan Simcere Pharmaceutical Co. Ltd. has disclosed kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Rpxds Co. Ltd. has described α-ketoglutarate-dependent dioxygenase FTO inhibitors reported to be useful for the treatment of obesity, diabetes, atherosclerosis and more.

Sporos Biodiscovery Inc. has divulged transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.

Viking Therapeutics Inc. has identified amylin analogues acting as calcitonin receptor (CALCR; CT-R) and amylin receptor agonists reported to be useful for the treatment of diabetes and obesity.

ST Pharm Co. Ltd. has synthesized pyrrolopyridine compounds reported to be useful for the treatment of HIV infections.

Rezolute Inc. has disclosed plasma kallikrein (KLKB1) inhibitors reported to be useful for the treatment of diabetic macular edema and uveitis.

CSPC Megalith Biopharmaceutical Co. Ltd. has described antibody-drug conjugates (ADCs) comprising anti-tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) antibodies covalently linked to cytotoxic drugs reported to be useful for the treatment of pancreatic and breast cancer.

Takeda Pharmaceutical Co. Ltd. has divulged polypeptides acting as gastric inhibitory polypeptide receptor (GIPR) agonists reported to be useful for the treatment of nausea and vomiting.